Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
17
Recruiting, any sponsor type, condition "Cushing"
By trial status
The same filters, counted in each status. Pick one to switch.
17 trials
Showing 1 to 17, recently updated first.
University of Texas Southwestern Medical CenterAcademic, hospital or other
NCT07361874 · 75 participants (planned) · Start Mar 5, 2026 · Primary completion May 31, 2030
Drug: Intervention 2: Semaglutide · For: Mild Autonomous Cortisol Secretion (MACS); Autonomous Cortisol Secretion (ACS); Subclinical Cushing's and 1 more
Sites: Dallas, Texas
Mayo ClinicAcademic, hospital or other
NCT07138274 · 90 participants (planned) · Start Oct 19, 2026 · Primary completion Jun 2031
Drug: Metyrapone 250 mg Oral Tablets; Placebo · For: Mild Autonomous Cortisol Secretion (MACS); Autonomous Cortisol Secretion (ACS)
Sites: Rochester, Minnesota
- Diagnostic Value of CXCR4-targeted PET/CT in ACTH-dependent and Independent Cushing's SyndromeRecruiting
Peking Union Medical College HospitalAcademic, hospital or other
NCT07350707 · 160 participants (planned) · Start Dec 25, 2025 · Primary completion Nov 1, 2026
Drug: 68Ga-Pentixafor · For: Cushing s Syndrome
Sites: Beijing, China
- Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's SyndromeRecruiting
RECORDATI GROUPIndustry
NCT07247162 · 63 participants (planned) · Start Aug 26, 2026 · Primary completion May 2028
Drug: Osilodrostat; Placebo · For: Hypertension; Hypercortisolemia; Cushing Syndrome
Sites: Jacksonville, Florida; Canton, Ohio; Weslaco, Texas
Mayo ClinicAcademic, hospital or other
NCT07460232 · 50 participants (planned) · Start Apr 27, 2026 · Primary completion Apr 2028
Drug: Fluoro-O-(2) fluoroethyl-L-tyrosine (FET) PET · For: Cushing Disease; Pituitary Adenoma
Sites: Rochester, Minnesota
Johns Hopkins UniversityAcademic, hospital or other
NCT07247058 · 10 participants (planned) · Start Feb 2, 2026 · Primary completion Dec 2028
Drug: Osilodrostat (Isturisa) · For: Mild Autonomous Cortisol Secretion (MACS)
Sites: Baltimore, Maryland
National Cancer Institute (NCI)NIH
NCT06246357 · 80 participants (planned) · Start Sep 23, 2024 · Primary completion Dec 1, 2029
Drug: [68Ga]Ga-PentixaFor · For: Hyperaldosteronism; Hypercortisolism; Cushing s Syndrome
Sites: Bethesda, Maryland
- Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)Pivotal-lookingRecruiting
Sparrow PharmaceuticalsIndustry
NCT07296484 · 1,500 participants (planned) · Start Nov 29, 2025 · Primary completion Dec 31, 2027
Drug: clofutriben; Placebo · For: Type 2 Diabetes; Cortisol Excess
Sites: Chandler, Arizona; Tucson, Arizona; Fountain Valley, California · 61 sites in all
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT02019706 · 80 participants (planned) · Start Feb 12, 2014 · Primary completion Dec 31, 2030
Drug: 68Ga-DOTATATE; 18F-DOPA · For: ACTH; Cushing's Syndrome
Sites: Bethesda, Maryland
University of MichiganAcademic, hospital or other
NCT06430528 · 12 participants (planned) · Start Jul 19, 2024 · Primary completion Oct 2027
Drug: Osilodrostat · For: Endogenous Cushing Syndrome; Adrenal Insufficiency; Hypercortisolism
Sites: Ann Arbor, Michigan
- Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing SyndromePivotal-lookingRecruiting
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT06635629 · 140 participants (planned) · Start Dec 12, 2024 · Primary completion Oct 1, 2028
Drug: Desmopressin; Dexamethasone · For: Cushing Syndrome
Sites: Bethesda, Maryland
- Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing DiseaseRecruiting
University of California, Los AngelesAcademic, hospital or other
NCT05971758 · 20 participants (planned) · Start Jan 16, 2025 · Primary completion Jan 2029
Drug: Fimepinostat · For: Cushing Disease
Sites: Los Angeles, California
- Myokines as Potential Biomarkers and Drivers of Sarcopenia in Metabolic and Endocrine DiseasesRecruiting
Cliniques universitaires Saint-Luc- Université Catholique de LouvainAcademic, hospital or other
NCT07703683 · 100 participants (planned) · Start Feb 19, 2026 · Primary completion Dec 31, 2056
Drug: GLP-1 Receptor Agonists · For: Diabetes; Obesity & Overweight; Cushing Syndrome and 4 more
Sites: Woluwe-Saint-Pierre - Sint-Pieters-Woluwe, Belgium
RECORDATI GROUPIndustry
NCT03708900 · 12 participants (planned) · Start Apr 28, 2021 · Primary completion Jul 21, 2027
Drug: LCI699 · For: Cushing Syndrome
Sites: San Francisco, California; Cape Coral, Florida; Chicago, Illinois · 15 sites in all
Mayo ClinicAcademic, hospital or other
NCT07104812 · 15 participants (planned) · Start Jan 14, 2026 · Primary completion Jan 2027
Drug: Osilodrostat 1 MG · For: Mild Autonomous Cortisol Secretion; Autonomous Cortisol Secretion (ACS)
Sites: Rochester, Minnesota
- Metyrapone Versus Osilodrostat in Patients With Metabolic Autonomous Cortisol Secretion (MACS)Recruiting
Laikο General Hospital, AthensAcademic, hospital or other
NCT07268222 · 150 participants (planned) · Start Dec 1, 2025 · Primary completion Nov 1, 2026
Drug: Metyrapone 250 mg Oral Tablets; Osilodrostat 1 MG · For: Mild Autonomous Cortisol Secretion (MACS)
Sites: Athens, Greece
IRCCS Azienda Ospedaliero-Universitaria di BolognaAcademic, hospital or other
NCT06801249 · 50 participants (planned) · Start Feb 23, 2021 · Primary completion Nov 30, 2024
Drug: Metarapone; Standardized antihypertensive therapy · For: Adrenal Incidentalomas; Cushing Syndrome
Sites: Bologna, Italy; Naples, Italy; Padova, Italy
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.